Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
25.93
-0.65 (-2.45%)
At close: Jul 10, 2025, 4:00 PM
26.12
+0.19 (0.73%)
After-hours: Jul 10, 2025, 4:49 PM EDT

Bright Minds Biosciences Income Statement

Millions CAD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020 2019
Period Ending
Mar '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 2019
Selling, General & Admin
1.871.442.22.552.310.12
Upgrade
Research & Development
3.461.18512.186.310.35
Upgrade
Operating Expenses
5.332.627.214.738.620.47
Upgrade
Operating Income
-5.33-2.62-7.2-14.73-8.62-0.47
Upgrade
Interest Expense
-0.03-0.01----
Upgrade
Interest & Investment Income
0.540.03----
Upgrade
Currency Exchange Gain (Loss)
1.55-0.010.010.010.15-
Upgrade
Other Non Operating Income (Expenses)
-0.19-0.2-0.19-0.24-0.18-0.01
Upgrade
EBT Excluding Unusual Items
-3.44-2.8-7.37-14.96-8.65-0.48
Upgrade
Asset Writedown
----0--
Upgrade
Pretax Income
-3.44-2.8-7.37-14.96-8.65-0.48
Upgrade
Net Income
-3.44-2.8-7.37-14.96-8.65-0.48
Upgrade
Net Income to Common
-3.44-2.8-7.37-14.96-8.65-0.48
Upgrade
Shares Outstanding (Basic)
644221
Upgrade
Shares Outstanding (Diluted)
644221
Upgrade
Shares Change (YoY)
39.99%15.87%50.58%37.64%148.42%74.24%
Upgrade
EPS (Basic)
-0.62-0.65-1.98-6.06-4.82-0.66
Upgrade
EPS (Diluted)
-0.63-0.65-1.98-6.06-4.82-0.66
Upgrade
EBIT
-5.33-2.62-7.2-14.73-8.62-0.47
Upgrade
Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q